These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Muñoz J; Wang Y; Jain P; Wang M Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781 [TBL] [Abstract][Full Text] [Related]
6. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Argyropoulos KV; Palomba ML Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023 [TBL] [Abstract][Full Text] [Related]
7. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia. Varettoni M; Matous JV Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088 [TBL] [Abstract][Full Text] [Related]
8. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia. Muñoz J; Paludo J; Sarosiek S; Castillo JJ Cells; 2022 Oct; 11(20):. PubMed ID: 36291152 [TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia]. Tao Y; Xu YL; Wang S; Wang L; Zhao WL Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):490-494. PubMed ID: 37550205 [No Abstract] [Full Text] [Related]
10. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556 [TBL] [Abstract][Full Text] [Related]
11. Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Lim KJC; Tam CS Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772 [No Abstract] [Full Text] [Related]
12. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069 [TBL] [Abstract][Full Text] [Related]
13. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia. Khan AM J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629099 [TBL] [Abstract][Full Text] [Related]
14. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. Deshpande A; Munoz J Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040 [TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia. Buske C Lancet Haematol; 2020 Feb; 7(2):e85-e86. PubMed ID: 31866282 [No Abstract] [Full Text] [Related]
17. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259 [TBL] [Abstract][Full Text] [Related]
19. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104 [TBL] [Abstract][Full Text] [Related]
20. Ibrutinib for the treatment of Waldenström macroglobulinemia. Chakraborty R; Kapoor P; Ansell SM; Gertz MA Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]